TFF3 and breast carcinoma: There was significant co-expression of TFF3 and AKT1 in breast carcinoma cases treated with neoadjuvant therapy (p = 0.0365) which supports the anti-apoptotic role of TFF3 (Fig. 7c and 8f), (Additional file 1: Table S3).